Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrinkmann, Joscha-
dc.contributor.authorExner, Lara-
dc.contributor.authorLuebbert, Christian-
dc.contributor.authorSadowski, Gabriele-
dc.date.accessioned2021-06-17T08:19:28Z-
dc.date.available2021-06-17T08:19:28Z-
dc.date.issued2020-11-23-
dc.identifier.urihttp://hdl.handle.net/2003/40263-
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-22136-
dc.description.abstractPurpose: This work proposes an in-silico screening method for identifying promising formulation candidates in complex lipid-based drug delivery systems (LBDDS). Method: The approach is based on a minimum amount of experimental data for API solubilites in single excipients. Intermolecular interactions between APIs and excipients as well as between different excipients were accounted for by the Perturbed-Chain Statistical Associating Fluid Theory. The approach was applied to the in-silico screening of lipid-based formulations for ten model APIs (fenofibrate, ibuprofen, praziquantel, carbamazepine, cinnarizine, felodipine, naproxen, indomethacin, griseofulvin and glibenclamide) in mixtures of up to three out of nine excipients (tricaprylin, Capmul MCM, caprylic acid, Capryol™ 90, Lauroglycol™ FCC, Kolliphor TPGS, polyethylene glycol, carbitol and ethanol). Results: For eight out of the ten investigated model APIs, the solubilities in the final formulations could be enhanced by up to 100 times compared to the solubility in pure tricaprylin. Fenofibrate, ibuprofen, praziquantel, carbamazepine are recommended as type I formulations, whereas cinnarizine and felodipine showed a distinctive solubility gain in type II formulations. Increased solubility was found for naproxen and indomethacin in type IIIb and type IV formulations. The solubility of griseofulvin and glibenclamide could be slightly enhanced in type IIIb formulations. The experimental validation agreed very well with the screening results. Conclusion: The API solubility individually depends on the choice of excipients. The proposed in-silico-screening approach allows formulators to quickly determine most-appropriate types of lipid-based formulations for a given API with low experimental effort.en
dc.language.isoende
dc.relation.ispartofseriesPharmaceutical research;37-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectLipid-based formulationsen
dc.subjectPC-SAFTen
dc.subjectSolubilityen
dc.subjectThermodynamic modelingen
dc.subject.ddc660-
dc.titleIn-silico screening of lipid-based drug delivery systemsen
dc.typeTextde
dc.type.publicationtypearticlede
dcterms.accessRightsopen access-
eldorado.secondarypublicationtruede
eldorado.secondarypublication.primaryidentifierhttps://doi.org/10.1007/s11095-020-02955-0de
eldorado.secondarypublication.primarycitationBrinkmann, J., Exner, L., Luebbert, C. et al. In-Silico Screening of Lipid-Based Drug Delivery Systems. Pharm Res 37, 249 (2020)de
Appears in Collections:Lehrstuhl Thermodynamik

Files in This Item:
File Description SizeFormat 
Brinkmann2020_Article_In-SilicoScreeningOfLipid-Base.pdf911.16 kBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons